Volume 70, Issue 5, Pages (November 2016)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

Volume 70, Issue 5, Pages (November 2016)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

European Urology Focus

Volume 70, Issue 6, Pages (December 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 56, Issue 6, Pages (December 2009)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 53, Issue 4, Pages (April 2008)

Volume 67, Issue 4, Pages (April 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Volume 69, Issue 5, Pages (May 2016)

Volume 69, Issue 1, Pages (January 2016)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 2, Pages (February 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 74, Issue 1, Pages (July 2018)

Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, Gerhardt Attard, Kim.

Volume 70, Issue 4, Pages (October 2016)

Prostate Cancer Detection: A View of the Future

Volume 70, Issue 5, Pages (November 2016)

Volume 66, Issue 3, Pages (September 2014)

Volume 66, Issue 5, Pages (November 2014)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 69, Issue 6, Pages (June 2016)

Volume 71, Issue 5, Pages (May 2017)

Volume 70, Issue 4, Pages (October 2016)

Luis Martínez-Piñeiro European Urology Supplements

Prostate Cancer Epidemic in Sight?

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 65, Issue 6, Pages (June 2014)

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 73, Issue 5, Pages (May 2018)

Volume 75, Issue 1, Pages (January 2019)

Volume 71, Issue 6, Pages (June 2017)

Volume 55, Issue 6, Pages (June 2009)

Volume 71, Issue 3, Pages (March 2017)

Volume 67, Issue 6, Pages (June 2015)

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 6, Pages (December 2016)

Volume 74, Issue 3, Pages (September 2018)

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Volume 75, Issue 3, Pages (March 2019)

Volume 74, Issue 6, Pages (December 2018)

Axel Heidenreich European Urology Supplements

European Urology Oncology

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer Adam Sharp,

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Volume 70, Issue 5, Pages 724-731 (November 2016) Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer Pasquale Rescigno, David Lorente, Diletta Bianchini, Roberta Ferraldeschi, Michael P. Kolinsky, Spyridon Sideris, Zafeiris Zafeiriou, Semini Sumanasuriya, Alan D. Smith, Niven Mehra, Anuradha Jayaram, Raquel Perez-Lopez, Joaquin Mateo, Chris Parker, David P. Dearnaley, Nina Tunariu, Alison Reid, Gerhardt Attard, Johann S. de Bono European Urology Volume 70, Issue 5, Pages 724-731 (November 2016) DOI: 10.1016/j.eururo.2016.02.055 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier curves for overall survival (OS) for a decrease in prostate-specific antigen of ≥30% at 4 wk as a dichotomous variable: (A) overall study population, (B) post-chemotherapy population, and (C) pre-chemotherapy population. CI=confidence interval; HR=hazard ratio calculated from Cox regression models. European Urology 2016 70, 724-731DOI: (10.1016/j.eururo.2016.02.055) Copyright © 2016 European Association of Urology Terms and Conditions